title: [Primary Prophylactic Administration of Pegfilgrastim in FOLFIRINOX Therapy for Locally Advanced Pancreatic Carcinoma].
abstract: FOLFIRINOX therapy has a high response rate for pancreatic carcinoma, but has serious adverse effects. FOLFIRINOX therapy was administered to 11 patients with locally advanced pancreatic carcinoma at our hospital. We investigated the usefulness of primary prophylactic administration of pegfilgrastim(PegG). In the group receiving PegG, as well as with onset of neutropenia and thrombocytopenia, febrile neutropenia was reduced. Rates of anorexia and fatigue were also lower than in those who did not receive PegG. The PegG group maintained a high average relative dose intensity, as well as a high response rate. Primary prophylactic administration of PegG in FOLFIRINOX therapy is valid for pancreatic carcinoma.
authors.affiliation: Dept. of Hepato-Biliary-Pancreatic Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Riki
authors.initials: R
authors.lastname: Ninomiya
authors.forename: Akiko
authors.initials: A
authors.lastname: Nakazawa
authors.forename: Youichi
authors.initials: Y
authors.lastname: Miyata
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mitsui
authors.forename: Masahiko
authors.initials: M
authors.lastname: Komagome
authors.forename: Akira
authors.initials: A
authors.lastname: Maki
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Ozawa
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Beck
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim